Vabysmo Real-World Data Show Durable Vision Gains Across Retinal Diseases
Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare
Sentiment
Positive
Importance
7
Price
$51.88
Mkt Cap
$334.884B
52W Low
$40.05
52W High
$60.85
52W Position
30% above low
Off High
15% below high
Rel. Volume
0.6× avg
Market data snapshot near publication time
RHHBY sits 30% above its 52-week low of $40.05.
Summary
Genentech presented VOYAGER study data at EURETINA 2026 showing Vabysmo's real-world effectiveness across wet AMD, DME, and RVO. Vision gains and anatomical improvements were consistent with Phase III results, with treatment intervals extending in months 7-12. The data reinforce Vabysmo's commercial positioning in a competitive ophthalmology market.
At the time of this announcement, RHHBY was trading at $51.88 on OTC in the Life Sciences sector, with a market capitalization of approximately $334.9B. The 52-week trading range was $40.05 to $60.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.
Price Chart
RHHBY - Latest Insights
RHHBY
Oct 01, 2026, 1:00 AM EDT
Price at Filing:
$51.88
Real-time Price:
$51.88
Change:
$0 (0%)
Market Cap:
$334.884B
RHHBY
Sep 30, 2026, 1:00 AM EDT
Price at Filing:
$52.25
Real-time Price:
$51.88
Change:
-$0.370 (-0.71%)
Market Cap:
$334.884B
RHHBY
Sep 21, 2026, 1:04 PM EDT
Price at Filing:
$55.36
Real-time Price:
$51.88
Change:
-$3.48 (-6%)
Market Cap:
$334.884B